Codex Genetics Partners with Pacific Edge to Bring Non-Invasive Bladder Cancer Testing to Hong Kong
Key Insights
Codex Genetics (search) announced an exclusive collaboration with Pacific Edge (search) to offer Cxbladder (search) genomic urine tests for bladder cancer detection and monitoring across Hong Kong hospitals and clinics.
The partnership provides access to three clinically validated tests that integrate genomic biomarker analysis with clinical algorithms to support urologists and oncologists in risk stratification and surveillance.
Cxbladder Triage (search) received "Grade A" evidence recognition in the updated American Urological Association (search) Microhematuria Guidelines, supported by the randomized controlled STRATA study.
Codex Genetics (search), a leading precision diagnostics company in Hong Kong, has announced an exclusive collaboration with Pacific Edge (search) to bring advanced bladder cancer diagnostics to hospitals and clinics across Hong Kong. The partnership will provide Hong Kong clinicians with access to the Cxbladder (search) suite of non-invasive genomic urine tests for bladder cancer detection and monitoring.
Comprehensive Diagnostic Portfolio
Under this collaboration, Codex Genetics (search) will offer access to Cxbladder (search)'s full range of clinically validated tests, including Cxbladder Detect (search), Cxbladder Monitor (search), and Cxbladder Triage (search). These precision urine-based tests are designed to support urologists and oncologists in the risk stratification and surveillance of urothelial bladder cancer by integrating genomic biomarker analysis with clinical algorithms to deliver actionable insights earlier in the patient care pathway.
Regulatory Recognition and Clinical Evidence
The partnership gains additional significance following a February 2025 update to the Microhematuria Guideline issued by the American Urological Association (search) (AUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (search) (SUFU). The amended guideline now includes Cxbladder Triage (search) and incorporates language supporting the use of urine-based biomarkers to reduce reliance on cystoscopy. Notably, Cxbladder Triage is mentioned specifically in the guidelines, supported with "Grade A" evidence from a randomized controlled trial—the STRATA study.
Clinical Impact and Global Experience
Bladder cancer represents the ninth most common cancer worldwide, with high recurrence rates contributing to its significant clinical and economic burden. Cxbladder (search) has demonstrated substantial real-world application, having been used in over 100,000 patients globally. The diagnostic platform is supported by more than 25 peer-reviewed clinical studies that demonstrate high sensitivity and negative predictive value.
"Our collaboration with Cxbladder (search) reflects Codex's continued commitment as a leading diagnostics company in Hong Kong to advance precision medicine across Asia," said Dr. Aldrin Yim, co-founder of Codex Genetics (search). "Bladder cancer is one of the most expensive cancers to manage due to its high recurrence rate and need for lifelong monitoring. By offering a reliable non-invasive alternative that can reduce the need for cystoscopy, we aim to enhance clinical workflows, allowing clinicians to prioritize time and resources on those who need it the most. This improves the quality of care for patients in both public and private healthcare systems."
Strategic Partnership Benefits
Dr. Peter Meintjes, CEO of Pacific Edge (search), emphasized the strategic value of the collaboration: "We are excited to partner with Codex Genetics (search) to expand access to Cxbladder (search) in Hong Kong. Codex's regional leadership in precision diagnostics makes them an ideal partner to deliver Cxbladder's value to clinicians and patients seeking reliable and less burdensome approaches to bladder cancer testing."
The adoption of Cxbladder (search) testing can reduce the need for unnecessary invasive procedures and optimize clinical decision-making, potentially transforming the standard of care for bladder cancer patients in Hong Kong. Clinicians interested in accessing Cxbladder testing can contact Codex Genetics (search) through their website for onboarding and access information.